ATE304604T1 - Adenovirus vektoren für gentherapie - Google Patents

Adenovirus vektoren für gentherapie

Info

Publication number
ATE304604T1
ATE304604T1 AT94920351T AT94920351T ATE304604T1 AT E304604 T1 ATE304604 T1 AT E304604T1 AT 94920351 T AT94920351 T AT 94920351T AT 94920351 T AT94920351 T AT 94920351T AT E304604 T1 ATE304604 T1 AT E304604T1
Authority
AT
Austria
Prior art keywords
gene therapy
adenovirus vectors
vectors
adenovirus
cells
Prior art date
Application number
AT94920351T
Other languages
English (en)
Inventor
Frank L Graham
Andrew Bett
Wael Haddara
Ludvik Prevek
Original Assignee
Frank L Graham
Andrew Bett
Wael Haddara
Ludvik Prevek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/250,885 external-priority patent/US6140087A/en
Application filed by Frank L Graham, Andrew Bett, Wael Haddara, Ludvik Prevek filed Critical Frank L Graham
Application granted granted Critical
Publication of ATE304604T1 publication Critical patent/ATE304604T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
AT94920351T 1993-06-24 1994-06-24 Adenovirus vektoren für gentherapie ATE304604T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8072793A 1993-06-24 1993-06-24
US08/250,885 US6140087A (en) 1993-06-24 1994-05-31 Adenovirus vectors for gene therapy
PCT/CA1994/000364 WO1995000655A1 (en) 1993-06-24 1994-06-24 Adenovirus vectors for gene therapy

Publications (1)

Publication Number Publication Date
ATE304604T1 true ATE304604T1 (de) 2005-09-15

Family

ID=22159231

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94920351T ATE304604T1 (de) 1993-06-24 1994-06-24 Adenovirus vektoren für gentherapie

Country Status (8)

Country Link
EP (1) EP0705344B8 (de)
JP (1) JP3532566B2 (de)
AT (1) ATE304604T1 (de)
AU (1) AU687829B2 (de)
CA (1) CA2166118C (de)
DE (1) DE69434486T2 (de)
ES (1) ES2249761T3 (de)
WO (1) WO1995000655A1 (de)

Families Citing this family (316)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
JP3816518B2 (ja) * 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE246252T1 (de) * 1994-08-16 2003-08-15 Crucell Holland Bv Von adenovirus abgeleitete rekombinante vektoren, für gentherapie
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
ES2240980T3 (es) * 1994-10-28 2005-10-16 The Trustees Of The University Of Pennsylvania Adenovirus mejorado y metodos de utilizacion del mismo.
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
FR2727867B1 (fr) * 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
CN100569297C (zh) 1995-02-28 2009-12-16 加利福尼亚大学董事会 基因转移介导的血管形成疗法
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US6019978A (en) 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US5698202A (en) * 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6197293B1 (en) 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US7011976B1 (en) 1997-03-03 2006-03-14 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
WO1997017937A2 (de) * 1995-11-17 1997-05-22 Franz Wolfgang M Gentherapeutisches nukleinsäurekonstrukt, seine herstellung und verwendung zur behandlung von herzerkrankungen
EP0866721A4 (de) * 1995-12-08 2003-06-04 Univ Alabama Birmingham Res Fo Adenovirale zielvektoren
US6132989A (en) * 1996-06-03 2000-10-17 University Of Washington Methods and compositions for enhanced stability of non-adenoviral DNA
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
WO1998032860A1 (en) * 1997-01-28 1998-07-30 Baxter International Inc. Methods for highly efficient generation of adenoviral vectors
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
EP1029052B1 (de) 1997-11-06 2010-08-04 Novartis Vaccines and Diagnostics S.r.l. Neisseriale antigene
DE69941567D1 (de) 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
CN1295617A (zh) 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子－血管内皮细胞生长因子vegf的突变体
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ES2294629T3 (es) 1998-05-01 2008-04-01 Novartis Vaccines And Diagnostics, Inc. Antigenos de neisseria y composiciones.
CA2359795A1 (en) * 1999-01-14 2000-07-20 Novartis Ag Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
EP1159439B1 (de) 1999-03-05 2014-01-08 Advec Inc. Verbessertes system für die konstruktion von adenoviralen vektoren
ES2397918T3 (es) 1999-04-30 2013-03-12 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
ES2564463T3 (es) 1999-10-29 2016-03-22 Glaxosmithkline Biologicals S.A. Péptidos antigénicos de Neisseriales
WO2001036640A2 (en) 1999-11-18 2001-05-25 Chiron Corporation Human fgf-21 gene and gene expression products
WO2001048164A2 (en) 1999-12-27 2001-07-05 The Regents Of The University Of California Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
EP1854476A3 (de) 2000-02-09 2008-05-07 Bas Medical, Inc. Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten
JP2003531583A (ja) 2000-03-08 2003-10-28 カイロン コーポレイション ヒトｆｇｆ−２３遺伝子および遺伝子発現産物
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
DE60134275D1 (de) 2000-06-15 2008-07-10 Novartis Vaccines & Diagnostic Polynukleotide zur bestimmung von kolonkrebs
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP2284182A1 (de) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nukleinsäuren und Proteine von Streptokokkengruppen A und B
CA2430379A1 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
DE60236212D1 (de) 2001-11-09 2010-06-10 Univ Georgetown Neue isoform des gefässendothelzell wachstumshemmers (vegi)
EP2335723A1 (de) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisierung gegen Chlamydia trachomatis
CA2472282A1 (en) 2002-01-08 2003-07-17 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
IL163988A0 (en) 2002-03-15 2005-12-18 Wyeth Corp Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
CA2479730A1 (en) 2002-03-21 2003-10-02 Sagres Discovery, Inc. Novel compositions and methods in cancer
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
EP1532161B1 (de) 2002-06-13 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Vektoren zur expression von hml-2-polypeptiden
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP2058408A3 (de) 2003-02-14 2009-09-09 Sagres Discovery, Inc. Therapeutische GPCR-Targets für Karzinome
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
CA2516454A1 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
ATE513471T1 (de) 2003-04-21 2011-07-15 Epeius Biotechnologies Corp Verfahren und zusammensetzungen zur behandlung von erkrankungen
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP1697534B1 (de) 2003-12-01 2010-06-02 Life Technologies Corporation Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
WO2005062955A2 (en) 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Agonist anti-trkc antibodies and methods using same
CN104292321A (zh) 2004-03-29 2015-01-21 株式会社嘉尔药物 新的半乳凝素9 突变体蛋白质及其用途
TWI367101B (en) 2004-04-07 2012-07-01 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
TR201808440T4 (tr) 2004-07-09 2018-07-23 Henry M Jackson Found Advancement Military Medicine Inc Hendra ve nipah virüsü G glikoproteininin çözünebilen formları.
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
CA2575663C (en) 2004-07-30 2013-04-23 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
WO2006042177A2 (en) 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
EP1858919B1 (de) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immungene von uropathogenen escherichia coli
WO2006110585A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes (prlr)
EP2062591A1 (de) 2005-04-07 2009-05-27 Novartis Vaccines and Diagnostics, Inc. CACNA1E in der Krebsdiagnose-Erkennung und -Behandlung
EP1879623B1 (de) 2005-05-02 2012-10-03 Genzyme Corporation Gentherapie für rückenmarkerkrankungen
PT3058959T (pt) 2005-05-02 2019-05-24 Genzyme Corp Terapia genética para distúrbios neurometabólicos
WO2007014169A2 (en) 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-cd26 antibodies and methods of use thereof
CA2626120C (en) 2005-11-14 2012-12-04 Rinat Neuroscience Corp. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
LT1986661T (lt) 2006-02-08 2018-12-10 Genzyme Corporation Nimano-piko a tipo ligos genų terapija
SG172684A1 (en) 2006-06-07 2011-07-28 Bioalliance Cv Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
LT2029742T (lt) 2006-06-07 2016-11-10 Genzyme Corporation Genų terapija, skirta amiotrofinei lateralinei sklerozei ir kitiems stuburo smegenų sutrikimams
PL2054431T3 (pl) 2006-06-09 2012-07-31 Novartis Ag Konformery adhezyn bakteryjnych
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
PT2066791E (pt) 2006-10-03 2012-12-05 Genzyme Corp Terapia génica para esclerose lateral amiotrófica e outros distúrbios da medula espinal
WO2008124176A2 (en) 2007-04-10 2008-10-16 The Administrators Of The Tulane Educational Fund Soluble and membrane-anchored forms of lassa virus subunit proteins
PL2158319T4 (pl) 2007-05-11 2016-04-29 Alexion Pharma Inc Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie
HUE027278T2 (en) 2007-05-16 2016-11-28 Brigham & Womens Hospital Inc Treatment of synucleinopathies
PL3252161T3 (pl) 2007-06-06 2022-03-07 Genzyme Corporation Terapia genowa dla lizosomalnych chorób spichrzeniowych
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR20170100071A (ko) 2007-09-28 2017-09-01 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
US20100278873A1 (en) 2007-11-08 2010-11-04 David Avigan Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
CN102216329A (zh) 2007-12-17 2011-10-12 辉瑞有限公司 间质性膀胱炎的治疗
ES2550757T3 (es) 2007-12-18 2015-11-12 Bioalliance C.V. Anticuerpos que reconocen un epítopo que contiene carbohidratos en CD43 y ACE expresados en células cancerosas y métodos de uso de los mismos
EP3023502A1 (de) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
US20110293608A1 (en) 2008-12-03 2011-12-01 The Johns Hopkins Univeristy Annexin a2 as immunological target
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
JP2012519482A (ja) 2009-03-06 2012-08-30 ノバルティス アーゲー クラミジア抗原
EP2411505A4 (de) 2009-03-26 2013-01-30 Univ California Mesenchymale stammzellen zur produktion hemmender rna zur krankheitsmodifikation
ES2607935T3 (es) 2009-03-30 2017-04-04 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
SI2510947T1 (sl) 2009-04-14 2016-05-31 Glaxosmithkline Biologicals S.A. Sestavki za imunizacijo proti Staphylococcus aureus
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
US20120283136A1 (en) 2009-06-24 2012-11-08 The University Of Southern California Compositions and methods for the rapid biosynthesis and in vivo screening of biologically relevant peptides
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
CA2767858C (en) 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
CN102770443A (zh) 2009-07-16 2012-11-07 诺华有限公司 脱毒大肠杆菌免疫原
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
MX2012010481A (es) 2010-03-11 2012-10-09 Rinat Neuroscience Corp Anticuerpos con union de antigenos dependiente del ph.
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
EP2563907B1 (de) 2010-04-28 2019-06-19 The J. David Gladstone Institutes Verfahren zur erzeugung von kardiomyozyten
CA2798703A1 (en) 2010-05-10 2011-11-17 The Regents Of The University Of California Endoribonuclease compositions and methods of use thereof
WO2011154553A2 (en) 2010-06-11 2011-12-15 Cellartis Ab Novel micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2663868A2 (de) 2010-12-01 2013-11-20 The University of North Carolina at Chapel Hill Verfahren und zusammensetzungen zur abzielung auf neovaskuläre wachstumsstellen
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
WO2013033636A2 (en) 2011-09-01 2013-03-07 University Of Southern California Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
AU2012335205A1 (en) 2011-11-11 2014-05-29 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
AU2012352429B2 (en) 2011-12-16 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
MX2014007644A (es) 2011-12-22 2014-09-26 Rinat Neuroscience Corp Anticuerpos antagonistas del receptor de hormona de crecimiento humana y metodos para su uso.
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
LT3241902T (lt) 2012-05-25 2018-06-25 The Regents Of The University Of California Būdai ir kompozicijos, skirti rnr nukreiptos tikslinės dnr modifikacijai ir rnr nukreiptos transkripcijos moduliacijai
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
JP6578206B2 (ja) 2012-07-19 2019-09-18 レッドウッド バイオサイエンス， インコーポレイテッド Ｃｄ２２に特異的な抗体およびその使用方法
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
HUE048780T2 (hu) 2012-08-16 2020-09-28 Ipierian Inc Tauopátia kezelésére szolgáló módszerek
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
AU2013337354A1 (en) 2012-11-05 2015-05-21 Genzyme Corporation Compositions and methods for treating proteinopathies
BR112015010722A2 (pt) 2012-11-09 2017-08-22 Pfizer Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos
EP2956557B1 (de) 2013-02-14 2018-07-11 The J. David Gladstone Institutes Zusammensetzungen und verfahren zur verwendung davon zur identifizierung von viruziden
AU2014216130B2 (en) 2013-02-15 2017-11-16 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof
JP2016519570A (ja) 2013-03-14 2016-07-07 エペイウス バイオテクノロジーズ コーポレイション 改善されたチミジンキナーゼ遺伝子
WO2014139182A1 (en) 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
CA3208188A1 (en) 2013-03-15 2014-09-25 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
KR20160005749A (ko) 2013-05-07 2016-01-15 리나트 뉴로사이언스 코프. 항-글루카곤 수용체 항체 및 이의 사용 방법
RS60883B1 (sr) 2013-06-10 2020-11-30 Ipierian Inc Metodi lečenja tauopatije
SG11201510369WA (en) 2013-06-25 2016-01-28 Univ Canberra Methods and compositions for modulating cancer stem cells
CN106103716A (zh) 2013-07-12 2016-11-09 乔治亚洲立大学研究基金会 Rna干扰dna聚合酶并抑制dna合成的方法及其复合物组分
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
DK3369435T3 (da) 2013-07-18 2019-11-25 Xalud Therapeutics Inc Sammensætning til behandling af inflammatorisk ledsygdom
BR112016002008B1 (pt) 2013-08-02 2021-06-22 Pfizer Inc. Anticorpos anti-cxcr4, seu uso, conjugado anticorpo-fármaco e composição farmacêutica
SG11201601408PA (en) 2013-09-18 2016-04-28 Univ Canberra Stem cell modulation ii
NZ719092A (en) 2013-11-13 2022-05-27 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
AU2014350051A1 (en) 2013-11-18 2016-07-07 Crispr Therapeutics Ag CRISPR-Cas system materials and methods
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
EP3835419A1 (de) 2013-12-12 2021-06-16 The Regents of The University of California Verfahren und zusammensetzungen zur modifizierung einer einzelsträngigen zielnukleinsäure
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
LT3119431T (lt) 2014-03-21 2024-03-12 Teva Pharmaceuticals International Gmbh Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, ir jų panaudojimo būdai
EP3139955B1 (de) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusionsproteine zur behandlung von krebs und zugehörige verfahren
WO2015175375A1 (en) 2014-05-13 2015-11-19 Short Jay M Conditionally active biological proteins
WO2015195531A2 (en) 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9546206B2 (en) 2014-08-08 2017-01-17 The Board Of Trustees Of The Leland Stanford Junior University High affinity PD-1 agents and methods of use
WO2016029262A1 (en) 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor
EP4074735A1 (de) 2014-08-28 2022-10-19 BioAtla, Inc. Bedingt aktive chimäre antigenrezeptoren für modifizierte t-zellen
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
WO2016036916A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
KR20170073593A (ko) 2014-09-09 2017-06-28 유넘 테라퓨틱스 키메라 수용체 및 면역 요법에서의 그의 용도
BR112017011900A2 (pt) 2014-12-05 2018-02-27 Alexion Pharma Inc tratamento de ataques com fosfatase alcalina recombinante
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
JP2018506530A (ja) 2015-01-30 2018-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脊柱軟膜下遺伝子送達システム
EP3268472B1 (de) 2015-03-13 2021-05-05 The Jackson Laboratory Dreikomponentiges crispr/cas-komplexsystem und verwendungen davon
AU2016243629B2 (en) 2015-03-30 2021-02-18 Beth Israel Deaconess Medical Center Compositions and methods of treating cancer
WO2016160966A1 (en) 2015-03-30 2016-10-06 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating renal cell cancer
WO2016160968A1 (en) 2015-03-30 2016-10-06 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating acute myeloid leukemia
US20180085398A1 (en) 2015-03-30 2018-03-29 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
US20180071340A1 (en) 2015-03-30 2018-03-15 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating multiple myeloma
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
SI3280440T1 (sl) 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana protitelesa proti C1S in načini uporabe
JP6960396B2 (ja) 2015-04-07 2021-11-05 ザ ジェイ． デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デビッド グラッドストーン 分裂終了細胞の細胞分裂を誘発するための方法
DK3283106T3 (da) 2015-04-13 2022-01-10 Pfizer Terapeutiske antistoffer og anvendelser deraf
US10967073B2 (en) 2015-05-07 2021-04-06 The Mclean Hospital Corporation Glucocerebrosidase gene therapy for Parkinson's disease
US10392607B2 (en) 2015-06-03 2019-08-27 The Regents Of The University Of California Cas9 variants and methods of use thereof
US11040094B2 (en) 2015-07-01 2021-06-22 Colleen M. O'Connor Compositions and methods for treating immunological dysfunction
WO2017011275A1 (en) 2015-07-10 2017-01-19 Nersissian Aram M Factor viii protein compositions and methods of treating hemophilia a
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
EA201890340A1 (ru) 2015-07-21 2018-09-28 Дайэкс Корп. Моноклональное антитело-ингибитор фактора xiia
EP3325010B1 (de) 2015-07-23 2023-06-21 The Regents of The University of California Antikörper gegen gerinnungsfaktor xia und verwendungen davon
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3331536A4 (de) 2015-08-03 2019-03-27 The Regents of The University of California Zusammensetzungen und verfahren zur modulierung der abhd2-aktivität
SG10201912817YA (en) 2015-08-19 2020-02-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
JP7074341B2 (ja) 2015-09-02 2022-05-24 イムテップ エス．アー．エス． 抗ｌａｇ－３抗体
MX2018003196A (es) 2015-09-15 2019-05-16 Scholar Rock Inc Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
EP3353297A1 (de) 2015-09-24 2018-08-01 Crispr Therapeutics AG Neuartige familie von rna-programmierbaren endonukleasen und deren verwendung in der genomeditierung und anderen anwendungen
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
ES2962651T3 (es) 2015-10-16 2024-03-20 Univ Columbia Composiciones y métodos para la inhibición de antígenos específicos de linaje
CN108289909A (zh) 2015-10-19 2018-07-17 巴尔的摩马里兰大学 用于产生工程改造的人原代血液树突细胞系的方法
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
CN108697762A (zh) 2015-11-20 2018-10-23 丹娜法伯癌症研究院 治疗癌症的组合物和方法
EP3397276A4 (de) 2015-12-30 2019-12-18 Kodiak Sciences Inc. Antikörper und konjugate davon
MX2018008416A (es) 2016-01-08 2019-11-11 Univ California Polipéptidos heterodímericos condicionalmente activos y métodos para su uso.
ES2904593T3 (es) 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
JP7372036B2 (ja) 2016-03-03 2023-10-31 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
WO2020047527A2 (en) 2018-09-02 2020-03-05 F1 Bioventures, Llc Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
CN116426490A (zh) 2016-03-19 2023-07-14 埃克苏马生物技术公司 淋巴细胞转导及其扩增调节的方法与组合物
WO2018009923A1 (en) 2016-07-08 2018-01-11 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulating the activity thereof
KR102489437B1 (ko) 2016-03-28 2023-01-16 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뉴런 과흥분성 치료를 위한 방법 및 조성물
US20190125848A1 (en) 2016-03-30 2019-05-02 Dana-Farber Cancer Institute, Inc. Dendritic cell-extracellular vesicle fusions and methods of using same
US11560412B2 (en) 2016-04-01 2023-01-24 University Of Maryland, Baltimore Compositions comprising GRIM-19 therapeutics and methods of use
IL295288B1 (en) 2016-04-04 2024-04-01 Bioverativ Usa Inc Anti-complement factor BB antibodies and their uses
HRP20221298T1 (hr) 2016-05-13 2022-12-23 Bioatla, Inc. Anti-ror2 protutijela, fragmenti protutijela, njihovi imunokonjugati i njihove uporabe
AU2017268348A1 (en) 2016-05-18 2018-10-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN109689096A (zh) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
WO2018053037A1 (en) 2016-09-13 2018-03-22 The Jackson Laboratory Targeted enhanced dna demethylation
US10578610B2 (en) 2016-09-20 2020-03-03 Washington University Peptide regulators of mitochondrial fusion and methods of use
JP7069138B2 (ja) 2016-10-12 2022-05-17 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗Ｃ１ｓ抗体およびその使用方法
US20180119141A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
AU2017356295A1 (en) 2016-11-14 2019-05-23 Beth Israel Deaconess Medical Center Compositions and methods of treating cancer
CA3042945A1 (en) 2016-11-14 2018-05-17 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2018119114A1 (en) 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3565834A1 (de) 2017-01-04 2019-11-13 The Research Institute at Nationwide Children's Hospital Antikörperfragmente zur behandlung von biofilmbedingten erkrankungen
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP7280827B2 (ja) 2017-01-18 2023-05-24 エクスマ バイオテック コーポレイション Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法
EP3571294A1 (de) 2017-01-18 2019-11-27 F1 Oncology, Inc. Verfahren zur transduktion und expansion von immunzellen und verwendungen davon
WO2018148246A1 (en) 2017-02-07 2018-08-16 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
SG10202109571PA (en) 2017-03-03 2021-10-28 Exuma Biotech Corp Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
US11198735B2 (en) 2017-03-03 2021-12-14 Rinat Neuroscience Corp. Anti-GITR antibodies and methods of use thereof
EP3596206A1 (de) 2017-03-16 2020-01-22 Pfizer Inc Tyrosinprototrophie
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
CN110785180B (zh) 2017-04-21 2024-04-02 贝勒医学院 溶瘤病毒疗法和免疫疗法
KR102356984B1 (ko) 2017-06-02 2022-01-28 화이자 인코포레이티드 Flt3에 특이적인 항체 및 이의 용도
US20180357361A1 (en) 2017-06-13 2018-12-13 Feliks Frenkel Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
CA3074839A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
WO2019051122A2 (en) 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS
EP3692370A2 (de) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Artikel und verfahren zur personalisierten krebstherapie
WO2019075220A1 (en) 2017-10-11 2019-04-18 Bioverativ Usa Inc. METHODS FOR INDUCING COMPLEMENT ACTIVITY
WO2019118935A1 (en) 2017-12-14 2019-06-20 Casebia Therapeutics Limited Liability Partnership Novel rna-programmable endonuclease systems and their use in genome editing and other applications
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
PE20210708A1 (es) 2018-02-01 2021-04-16 Pfizer Anticuerpos especificos para cd70 y sus usos
PE20211299A1 (es) 2018-02-01 2021-07-20 Pfizer Receptores de antigeno quimericos dirigidos a cd70
US11667949B2 (en) 2018-02-15 2023-06-06 The Trustees Of Princeton University Reporter construct and biosensor for interferon second messenger 2-5A
KR20200128116A (ko) 2018-02-28 2020-11-11 화이자 인코포레이티드 Il-15 변이체 및 이의 용도
AU2019234926A1 (en) 2018-03-15 2020-10-08 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
JP2021518139A (ja) 2018-03-19 2021-08-02 クリスパー セラピューティクス アーゲー 新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用
CA3100829A1 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
CA3100828A1 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for cd3 and uses thereof
WO2020033837A1 (en) 2018-08-09 2020-02-13 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
EP3844187A1 (de) 2018-08-28 2021-07-07 Vor Biopharma, Inc. Genetisch veränderte hämatopoetische stammzellen und verwendungen davon
JP7450945B2 (ja) 2018-08-30 2024-03-18 テナヤ セラピューティクス， インコーポレイテッド ミオカルディンおよびａｓｃｌ１を用いた心細胞リプログラミング
US20210338783A1 (en) 2018-10-05 2021-11-04 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
TW202039542A (zh) 2018-12-19 2020-11-01 美商庫爾生物製藥有限公司 多聚體ｔ細胞調節多肽及其使用方法
AU2020231391A1 (en) 2019-03-05 2021-10-28 Takeda Pharmaceutical Company Limited Conditionally activated binding proteins containing Fc regions and moieties targeting tumor antigens
WO2020181062A1 (en) 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3935156A4 (de) 2019-03-07 2022-12-28 The Regents of The University of California Crispr-cas-effektorpolypeptide und verfahren zu deren verwendung
SG11202109741VA (en) 2019-03-12 2021-10-28 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
WO2020206033A1 (en) 2019-04-02 2020-10-08 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CA3146077A1 (en) 2019-07-03 2021-02-18 Bostongene Corporation Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
BR112021026890A2 (pt) 2019-07-08 2022-03-15 Res Inst Nationwide Childrens Hospital Composições de anticorpo para interromper biofilmes
US20230137971A1 (en) 2019-07-11 2023-05-04 Tenaya Therapeutics Inc. Cardiac cell reprogramming with micrornas and other factors
WO2021020979A1 (en) 2019-07-31 2021-02-04 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy
EP4041308A1 (de) 2019-10-07 2022-08-17 University of Virginia Patent Foundation Modulation von lymphgefässen bei neurologischen erkrankungen
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
EP4041773A1 (de) 2019-10-11 2022-08-17 Beth Israel Deaconess Medical Center, Inc. Anti-tn-antikörper und verwendungen davon
JP7385742B2 (ja) 2019-10-23 2023-11-22 ジェネンメド カンパニー リミテッド ヘルパープラスミドベースのガットレスアデノウイルス生産システム
WO2021113736A1 (en) 2019-12-05 2021-06-10 Massachusetts Institute Of Technology Single-domain antibody to chloramphenicol
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CN115552022A (zh) 2020-03-02 2022-12-30 特纳亚治疗股份有限公司 由心肌细胞表达的微rna控制的基因载体
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
CA3182969A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
AU2021308586A1 (en) 2020-07-17 2023-03-02 Pfizer Inc. Therapeutic antibodies and their uses
US20230287455A1 (en) 2020-07-30 2023-09-14 Pfizer Inc. Cells Having Gene Duplications and Uses Thereof
WO2022032085A1 (en) 2020-08-07 2022-02-10 The Jackson Laboratory Targeted sequence insertion compositions and methods
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
US20240029829A1 (en) 2020-12-04 2024-01-25 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022187289A1 (en) 2021-03-01 2022-09-09 Exuma Biotech Corp. Methods and compositions for the delivery of retroviral particles
WO2022232615A1 (en) 2021-04-29 2022-11-03 Bostongene Corporation Machine learning techniques for estimating tumor cell expression complex tumor tissue
WO2022259190A1 (en) 2021-06-10 2022-12-15 Janssen Biotech, Inc. Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof
EP4101928A1 (de) 2021-06-11 2022-12-14 Bayer AG Programmierbare typ-v-rna-endonukleasesysteme
CA3222950A1 (en) 2021-06-11 2022-12-15 Bayer Aktiengesellschaft Type v rna programmable endonuclease systems
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
EP4144841A1 (de) 2021-09-07 2023-03-08 Bayer AG Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
AU2022349103A1 (en) 2021-09-27 2024-03-28 Sotio Biotech Inc. Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
WO2023091909A1 (en) 2021-11-16 2023-05-25 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
WO2023102388A1 (en) 2021-11-30 2023-06-08 Sanofi Pasteur Inc. Human metapneumovirus viral vector-based vaccines
WO2023114658A1 (en) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anti-abcb1 antibodies
WO2023118068A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023147177A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
WO2023168305A1 (en) 2022-03-01 2023-09-07 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
WO2023237587A1 (en) 2022-06-10 2023-12-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2024005863A1 (en) 2022-06-30 2024-01-04 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
EP4299733A1 (de) 2022-06-30 2024-01-03 Inari Agriculture Technology, Inc. Zusammensetzungen, systeme und verfahren zum genomeditieren
WO2024005864A1 (en) 2022-06-30 2024-01-04 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
EP4299739A1 (de) 2022-06-30 2024-01-03 Inari Agriculture Technology, Inc. Zusammensetzungen und verfahren zur genomeditierung
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
WO2024040208A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024044659A1 (en) 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Constitutively active g protein-coupled receptor compositions and methods of use thereof
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1993019092A1 (fr) * 1992-03-19 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr
ES2312164T3 (es) * 1992-09-25 2009-02-16 Aventis Pharma S.A. Vectores de adenovirus para la transferencia de genes extraños en celulas del sistema nervioso central, particularmente en el cerebro.
EP0911413A3 (de) * 1992-12-03 2000-11-15 Genzyme Corporation Mindestadenovirus-Vector zur Gentherapie

Also Published As

Publication number Publication date
JP2002509422A (ja) 2002-03-26
CA2166118A1 (en) 1995-01-05
EP0705344B1 (de) 2005-09-14
ES2249761T3 (es) 2006-04-01
CA2166118C (en) 2007-04-17
AU7118494A (en) 1995-01-17
AU687829B2 (en) 1998-03-05
DE69434486D1 (de) 2006-01-26
EP0705344B8 (de) 2006-05-10
EP0705344A1 (de) 1996-04-10
WO1995000655A1 (en) 1995-01-05
JP3532566B2 (ja) 2004-05-31
DE69434486T2 (de) 2006-07-06

Similar Documents

Publication Publication Date Title
DE69434486D1 (de) Adenovirus vektoren für gentherapie
GEP20012559B (en) Complementary Adenoviral Vector Systems and Cells Lines
PT832264E (pt) Plasmideo para a transferencia de acidos nucleicos a celulas e metodos de utilizacao.
NZ332297A (en) Nucleic acid of a chimeric repair vector and use in repairing cell mutations
ES2084703T3 (es) Mutante tipo 1 del virus herpes simple.
LTIP1826A (en) Process for preparing transformed prokaryotic host cell, stable gene amplification in the chromosome dna of prokaryotic microorganisms
IL133708A0 (en) Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination thereof
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
EP1156108A3 (de) Verwendung einer Exo-Nukleotidprobe in der Genklonierung
AU1606897A (en) Thymidine kinase variants, corresponding nucleic acid sequences and their use in gene therapy
HUP9900868A2 (hu) Heterológ gének kromoszomális expressziója bakteriális sejtekben
HK1047129B (zh) 真核細胞的序列特異性dna重組
AU682140B2 (en) Multidrug resistance gene
AU7614696A (en) Integrin-linked kinase, its inhibitors and methods of medical treatment using these inhibitors, gene therapy and pseudo-substrate inhibitors
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
HUP9904329A2 (hu) Herpeszvirus saimiri mint vírusvektor
BR9811014A (pt) "região concentrada reguladora de gene especìfica para semente precoce"
Welter et al. DNA curvature in front of the human mitochondrial L-strand replication origin with specific protein binding
AU2294102A (en) Mutant muscle-specific enhancers
GB0211459D0 (en) Plasmid stabilisation in vivo
GR3007612T3 (de)
DE69940848D1 (de) (-)-strang rns virusvektor für nervenzellen
DK0654268T3 (da) Reversering af fænotypen af med transskriptionsfaktor IRF-1 transformerede celler
EP1214942A3 (de) Verwendung von mit Bacteriophagen, die ein tumorspezifisches und/oder tumorassoziliertes Antigen auf ihrer Oberfläche tragen, beladenen dendritischen Zellen zur Behandlung von Tumoren
CA2347371A1 (en) HEMATOPOIETIC REGULATION FACTORS AND METHODS OF USE

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties